guest column

Houston expert: How technology can be used to bridge the health equity gap

As the health care industry continues to evolve, experience management technology will play an increasingly important role in addressing health equity gaps and improving the health and well-being of patients across the globe. Photo via Getty Images

Progressively over the last decade, the health care industry has become increasingly aware of the role that social determinants of health play in the health outcomes of patients.

Social determinants of health, or SDOH, are the conditions in which people are born, grow, live, work, and age, and they have a significant impact on a person's health and well-being. Examples of SDOH include income, education level, housing, and access to healthy food.

One of the key challenges facing health care organizations and providers is how to address health equity gaps, which are the differences in health outcomes between different populations. Health equity gaps are often caused by social determinants of health, and they can be particularly pronounced among vulnerable populations such as low-income communities, racial and ethnic minorities, and those living in rural areas.

Experience management technology has emerged as a powerful tool for addressing these equity gaps. This technology uses feedback, behaviors, and other relevant SDOH data in order to understand the unique needs of different populations and develop targeted interventions to improve their health outcomes.

One of the key ways that experience management technology can help decrease health equity gaps is by segmenting populations by social determinants of health. By collecting data on patients' demographics, such as their age, race, income, and education level, health care organizations can gain a better understanding of the SDOH that are most relevant to each population. This information can be used to develop personalized actions that address the specific needs of each population, rather than relying on a one-size-fits-all approach.

For example, health care organizations could use experience management technology to gather feedback from patients on their access to healthy food. By segmenting the patient population by zip code, health care organizations could identify patients in rural areas who do not have easy access to quality care facilities and providers. These patients could then be targeted with interventions such as transportation assistance programs or care coordination programs, which could help address their specific needs.

In addition to segmenting populations by social determinants of health, experience management technology can also help health care organizations gather insights into patient behaviors. By integrating data on patients' health behaviors, such as adherence to treatment or missed appointments, health care organizations can develop targeted interventions that encourage healthy behaviors.

For example, health care providers could use experience management technology to collect data on patients' treatment habits. Patients who report low adherence to treatment could be targeted with interventions such as treatment education programs or care coaching, which could help them develop healthier habits over time.

Finally, experience management technology can help health care organizations gain insight into their patient’s end to end journey. By integrating data from multiple sources, such as electronic health records, patient feedback, and social determinants of health data, health care organizations can develop a more comprehensive understanding of patients' health needs and brand expectations. This unified illustration allows health care organizations to improve business outcomes such as lower readmission rates, and create loyal patients that will refer their friends and family in the most important and sensitive moments in their lives.

In conclusion, experience management technology has emerged as a powerful tool for addressing health equity gaps by segmenting populations by social determinants of health, understanding and acting on their unique needs through feedback, behaviors, and dynamic integrations. By leveraging this technology, health care organizations can develop unique solutions that improve the health outcomes of vulnerable populations, such as low-income communities, racial and ethnic minorities, and those living in rural areas.

As the health care industry continues to evolve, experience management technology will play an increasingly important role in addressing health equity gaps and improving the health and well-being of patients across the globe.

------

Ariel Jones is the head of health care provider solution strategy for Qualtrics XM, an American Experience Management company providing software solutions for customer and employee experience.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted